SURMOUNT-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
Definition
The pivotal phase 3 of tirzepatide 5/10/15 mg weekly against placebo in 2,539 adults with overweight or obesity (Jastreboff et al., NEJM 2022, PMID 35658024). Mean weight loss 20.9% at 15 mg over 72 weeks — the figure that made tirzepatide the drug people ask for by name.
Tirzepatide vs semaglutide head-to-head →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Major trials
Where the evidence lives
- Tirzepatide vs semaglutide head-to-head
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers